--- title: "Guardant Health | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 301.67 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285659279.md" datetime: "2026-05-08T03:40:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285659279.md) - [en](https://longbridge.com/en/news/285659279.md) - [zh-HK](https://longbridge.com/zh-HK/news/285659279.md) --- # Guardant Health | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 301.67 M Revenue: As of FY2026 Q1, the actual value is USD 301.67 M, beating the estimate of USD 279.06 M. EPS: As of FY2026 Q1, the actual value is USD -0.85, missing the estimate of USD -0.806. EBIT: As of FY2026 Q1, the actual value is USD -131.15 M. #### First Quarter 2026 Financial Highlights **Total Revenue**Guardant Health, Inc. reported total revenue of $301.7 million for the first quarter of 2026, marking a 48% increase compared to $203.5 million in the same period in 2025. - **Oncology Revenue**: This segment generated $205.0 million, representing a 36% increase, with approximately 86,000 oncology tests performed, a 47% increase from the prior year’s $150.6 million. - **Biopharma & Data Revenue**: Revenue from this segment was $53.0 million, an increase of 17% compared to $45.4 million in the prior year period. - **Screening Revenue**: This segment saw $41.6 million in revenue, driven by approximately 44,000 Shield screening tests, showing over 600% growth from $5.7 million and 9,000 tests in the prior year period. - **Licensing and Other Revenue**: This accounted for $2.1 million, up from $1.9 million in the prior year period. **Gross Profit (GAAP)**GAAP gross profit was $196.7 million for the first quarter of 2026, a 53% increase from $128.7 million in the prior year period. **Gross Margin (GAAP)**GAAP gross margin for the first quarter of 2026 was 65%, an increase from 63% in the prior year period. **Non-GAAP Gross Profit**Non-GAAP gross profit reached $200.1 million for the first quarter of 2026, a 52% increase from $131.3 million in the prior year period. **Non-GAAP Gross Margin**Non-GAAP gross margin was 66% for the first quarter of 2026, compared to 65% for the first quarter of 2025. **Operating Expenses (GAAP)**GAAP operating expenses were $318.1 million for the first quarter of 2026, compared to $239.8 million for the prior year period. - **Cost of Revenue**: This was $104.9 million for the first quarter of 2026, up from $74.7 million in the prior year period. - **Research and Development Expense**: This amounted to $91.0 million for the first quarter of 2026, compared to $88.5 million in the prior year period. - **Sales and Marketing Expense**: This was $169.1 million for the first quarter of 2026, an increase from $104.3 million in the prior year period. - **General and Administrative Expense**: This totaled $57.9 million for the first quarter of 2026, compared to $46.9 million in the prior year period. **Non-GAAP Operating Expenses**Non-GAAP operating expenses were $268.1 million for the first quarter of 2026, compared to $199.6 million for the prior year period. **Net Loss (GAAP)**GAAP net loss was -$112.1 million for the first quarter of 2026, compared to -$95.2 million for the prior year period. **Non-GAAP Net Loss**Non-GAAP net loss was -$58.7 million for the first quarter of 2026, compared to -$61.1 million for the prior year period. **Adjusted EBITDA Loss**Adjusted EBITDA loss was -$58.9 million for the first quarter of 2026, compared to a -$58.5 million loss for the prior year period. #### Cash Flow **Free Cash Flow**Free cash flow was -$71.2 million for the first quarter of 2026, compared to -$67.1 million for the prior year period. **Cash, Cash Equivalents, Restricted Cash and Marketable Securities**As of March 31, 2026, Guardant Health, Inc. held $1.2 billion in cash, cash equivalents, restricted cash, and marketable securities. **Net Cash Used in Operating Activities**Net cash used in operating activities was -$65.6 million for the first quarter of 2026, compared to -$62.7 million for the prior year period. #### 2026 Guidance Guardant Health, Inc. increased its full year 2026 revenue guidance to a range of $1.30 to $1.32 billion, representing 32% to 34% growth. Oncology revenue is now projected to grow 28% to 29%, with volume growth exceeding 35%, while screening revenue is expected to be between $186 million and $198 million, driven by 230,000 to 245,000 Shield tests. The company anticipates non-GAAP gross margin in the range of 64% to 65% and expects free cash flow burn to be $185 million to $195 million, an improvement from $233 million in 2025. ### Related Stocks - [GH.US](https://longbridge.com/en/quote/GH.US.md) ## Related News & Research - [Pictet Asset Management Holding SA Sells 89,386 Shares of Guardant Health, Inc. $GH](https://longbridge.com/en/news/284963012.md) - [Guardant Health (GH) Earnings Spotlight Revenue Growth Versus Persistent Losses Challenges Premium Valuation Narratives](https://longbridge.com/en/news/285808535.md) - [Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results | GH Stock News](https://longbridge.com/en/news/272189132.md) - [Guardant Health (GH) Valuation Check After TRICARE Coverage Win For Shield Blood Test](https://longbridge.com/en/news/272304771.md) - [Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families | GH Stock News](https://longbridge.com/en/news/271937376.md)